Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R M

Trial Details

NCT ID
NCT06158841
Phase
PHASE3
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Etentamig
  • Carfilzomib
  • Pomalidomide
  • Elotuzumab
  • Selinexor
  • Bortezomib
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Berkeley, California, United States|37.87159,-122.27275
  • Fullerton, California, United States|33.87029,-117.92534
  • Loma Linda, California, United States|34.04835,-117.26115

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance of \<= 2.
  • Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol.
  • Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment:
  • Serum M-protein \>= 0.5 g/dL (\>= 5 g/L).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →